Efficacy and acceptability of early mifepristone-misoprostol medical abortion in Ukraine: Results of two clinical trials

European Journal of Contraception and Reproductive Health Care

Volumn 18, Issue 2, 2013, Pages 112-119

  Raghavan, Sheila ^a   Maistruk, Galina ^b   Shochet, Tara ^a   Bannikov, Vladimir ^b   Posohova, Svetlana ^c   Zhuk, Svetlana ^d   Lishchuk, Vladimir ^e   Winikoff, Beverly ^a  

^a GYNUITY HEALTH PROJECTS   (United States)

^b Women Health and Family Planning   (Ukraine)

^c Central District Maternity House   (Ukraine)

^d Clinical Maternity Hospital N2   (Ukraine)

^e Central Military Clinical Hospital   (Ukraine)

Author keywords

Medical abortion; Mifepristone; Misoprostol; Ukraine

Indexed keywords

MIFEPRISTONE; MISOPROSTOL; MTPILL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DILATION AND EVACUATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL ABORTION; PRIORITY JOURNAL; UKRAINE;

ABORTIFACIENT AGENTS, NONSTEROIDAL; ABORTIFACIENT AGENTS, STEROIDAL; ABORTION, INDUCED; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, SUBLINGUAL; ADULT; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIFEPRISTONE; MISOPROSTOL; PATIENT ACCEPTANCE OF HEALTH CARE; PREGNANCY; PROSPECTIVE STUDIES; SELF ADMINISTRATION; UKRAINE; YOUNG ADULT;

EID: 84875206535     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2013.769951     Document Type: Article

References (22)

1. International Consortium for Medical Abortion: ICMA Publications [ Internet]. Countries abortion profi le: Ukraine. Chisinau, Moldova: ICMA. Accessed 10 November 2012 from: http://www.medicalabortionconsortium.org/ country/UA/.
2. Ukraine Ministry of Health. Ministry of Health annual statistical report 2010.
3. Levchuk N, Perelli-Harris B. Declining fertility in Ukraine: What is the role of abortion and contraception? Rostock, Germany: Max Planck Institute for Demographic Research 2009. MPIDR Working Paper No.: WP-2009-045.
4. Hajri S, Blum J, Gueddana N, et al. Expanding medical abortion in Tunisia: Women' sexperiences from amulti-site expansion study. Contraception 2004; 70: 487-91.
5. Karki C, Pokharel H, Kushwaha A, et al. Acceptability and feasibility of medical abortion in Nepal. Int JGynaecol Obstet 2009; 106: 39-42.
6. Shannon C, Wiebe E, Jacot F, et al. Regimens of misoprostol with mifepristone for early medical abortion: Arandomised trial. BJOG 2006; 113: 621-8.
7. Bracken H, Gliozheni O, Kati K, et al. Medical Abortion Research Group. Mifepristone medical abortion in Albania: Results from apilot clinical research study. Eur J Contracept Reprod Health Care 2006; 11: 38-46.
8. Dahiya K, Mann S, Nanda S. Randomized trial of oral versus sublingual misoprostol 24 hafter mifepristone for medical abortion. Arch Gynecol Obstet 2011; 284: 59-63.
9. Raghavan S, Comendant R, Digol I, et al. Two-pill regimens of misoprostol after mifepristone medical abortion through 63 days' gestational age: Arandomized controlled trial of sublingual and oral misoprostol. Contraception 2009; 79: 84-90.
10. Ngoc NT, Nhan VQ, Blum J, et al. Is home-based administration of prostaglandin safe and feasible for medical abortion? Results from amultisite study in Vietnam. BJOG 2004; 111: 814-9.
11. Bracken H; Family Planning Association of India (F PAI); Gynuity Health Projects Research Group for Simplifying Medical Abortion in India. Home administration of misoprostol for early medical abortion in India. Int JGynaecol Obstet 2010; 108: 228-32.
12. Boersma AA, Meyboom-de Jong B, Kleiverda A. Mifepristone followed by home administration of buccal misoprostol for medical abortion up to 70 days of amenorrhoea in ageneral practice in Cura ç ao. Eur JContracept Reprod Health Care 2011; 16: 61-6.
13. Raghavan S, Comendant R, Digol I, et al. Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days' LMP: Arandomized controlled trial. Contraception 2010; 82: 513-9.
14. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation. Termination of pregnancy with reduced doses of mifepristone. BMJ 1993; 307: 532-7.
15. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: Arandomised trial. BJOG 2000; 107: 524-30.
16. WHO. Frequently asked clinical questions about medical abortion. Geneva: World Health Organization 2007 Accessed 10 11 12 from: http://www.who.int/ reproductivehealth/publications/unsafe-abortion/9241594845/en/
17. Ukraine Ministry of Health. Clinical protocol " Comprehensive care for unwanted pregnancies " No. 1177 (2010).
18. Mundle S, Elul B, Anand A, et al. Increasing access to safe abortion services in rural India: Experiences with medical abortion in aprimary health center. Contraception 2007; 76: 66-70.
19. Coyaji K, Elul B, Krishna U, et al. Mifepristonemisoprostol abortion: Atrial in rural and urban Maharashtra, India. Contraception 2002; 66: 33-40.
20. Tran NT, Jang MC, Choe YS, et al. Feasibility, effi cacy, safety, and acceptability of mifepristone-misoprostol for medical abortion in the Democratic People' sRepublic of Korea. Int JGynaecol Obstet 2010; 109: 209-12.
21. Clark W, Bracken H, Tanenhaus J, et al. Alternatives to aroutine follow-up visit for early medical abortion. Obstet Gynecol 2010; 115: 264-72.
22. Blum J, Shochet T, Lynd K, et al. Can at-home semiquantitative pregnancy tests serve as areplacement for clinical follow-up of medical abortion: AUnited States study. Contraception 2012; 86: 757-62.